Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer

Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer (Original Article, N Engl J Med 2017;377:122-131). The authors' disclosure statement was omitted from the print edition: “Dr. von Minckwitz reports receiving grant support paid to his institution from Pfizer, Celgene, Novartis, Teva, Amgen, AbbVie, Vifor, and Myriad; Dr. Zardavas, receiving grant support paid to his institution from Roche/Genentech, Novartis, Pfizer, Tesaro, and Puma Biotechnology; Dr. Benyunes, being employed by Genentech; Dr. Viale, receiving advisory board fees from AstraZeneca, Merck, and Bristol-Myers Squibb; Dr. Arahmani, receiving grants paid to her institution from Novartis, Pfizer, Puma Biotechnology, TESARO, and AstraZeneca; Ms. Clark, being employed by Roche/Genentech and named as an inventor on a patent related to “Uses for and article of manufacture including HER2 dimerization inhibitor pertuzumab” (PCT/US2012/059683); Dr. Knott, being employed by Hoffmann La Roche; Dr. Yardley, receiving speaker's fees paid to her institution from Genentech; Dr. Gelber, receiving grants paid to his institution from Novartis, GlaxoSmithKline, Pfizer, Merck, Ferring, Ipsen, Celgene, and Roche; and Dr. Piccart, receiving consulting fees from Roche/Genentech. No other potential conflict of interest relevant to this article was reported.” The article is correct at NEJM.org.